Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-amoxicillin dual therapy vs furazolidone-containing bismuth quadruple therapy for Helicobacter pylori eradication
ChiCTR2200064872Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Nov 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan, amoxicillin, furazolidone and bismuth subcitrate in Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: eradication rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillinfurazolidonebismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200064872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064872.